Question 1

What are the potential side effects of ONT01, gemcitabine, and nab-paclitaxel?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma clinical trial (NCT06904378). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma clinical trial (NCT06904378). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma clinical trial (NCT06904378). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or procedures I will need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma clinical trial (NCT06904378). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I do if I experience side effects or complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma clinical trial (NCT06904378). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma clinical trial (NCT06904378). Contact the study team or your healthcare provider for specific answers.

What this study is about